Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!! -- Ignore unavailable to you. Want to Upgrade?

To: Stephen O who wrote (87)	6/6/2000 12:25:00 AM
From: Spiney	Respond to of 94

IGT's underwriter forms syndicate Now we should finally get some exposure in the market! IGT Pharma Inc IGT Shares issued 10,456,462 Jun 2 close $1.37 Mon 5 Jun 2000 News Release Mr. Bruce Schmidt reports Dominick and Dominick Securities Inc. of Toronto, lead underwriter of IGT's current $6-million financing, has formed a syndicate with Pacific International Securities Inc. and Salman Partners Inc., both of Vancouver. Each firm employes a biotech analyst with extensive knowledge of the sector thus enabling them to provide research reports and the maintenance of after-market interest. The use of proceeds of the financing will expand and accelerate IGT's drug development capabilities with enhanced in-house preclinical research programs as well as continued broad-based testing of its lead CNS compounds. As reported earlier, IGT has received the results of animal trials which confirm the ability to prevent the damage associated with stroke using IGT's new drug, IGT440103. The purpose of the animal study was to replicate the conditions of a human stroke by causing a temporary interruption of blood supply to the brain. As would be the case with human medical intervention, the blood supply to the animal is restored and the drug then administered by intravenous injection. The braind can then be evaluated as to the extent of brain cell damage. A critical design feature of IGT's new drug platform is in the ability for the drug to cross the blood-brain barrier, a protective mechanism in humans as well as animals, and a major challenge to neurological drug development. IGT incorporates molecular design in such a way that the blood-brain barrier ignores the presence of the drug thus allowing it to pass into the brain. IGT440103 is one of 34 drug candidates so far discovered by IGT that are designed to work at a brain receptor system called the mGluRs. This new treatment paradigm promises more specifically acting drugs without the side effects associated with many of today's approved neurological compounds. Further studies are under way and planned for the treatment of human conditions such as anxiety, epilepsy, neuropathic pain and drug dependence. Management also wishes to announce the setting of 75,000 incentive stock options at a price of $1.25 per share exercisable over a period of five years.

To: Stephen O who wrote (87)	9/18/2000 11:11:40 AM
From: Spiney	Read Replies (1) \| Respond to of 94

Hi Stephen, One comment on your last post from way back: When I spoke to the company I was told they were doing work on dogs - something to do with strokes... My most recent e-mail from the company informs me that things are progressing very well and they are in the last stages of phase I on AVLB. This is the most difficult stage due to the fact that they are dealing with terminal patients who will frequently drop out of a program because of the obvious emotional burden. The financing was supposed to close on the 15th - the Company confirmed that they were still on track so we should have news soon in that regard...which should give the stock price a nice lift. spiney